Published in PLoS Pathog on February 19, 2010
Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol (2013) 1.75
Human pathogenic hantaviruses and prevention of infection. Hum Vaccin (2011) 1.40
Longitudinal analysis of the human T cell response during acute hantavirus infection. J Virol (2011) 1.09
CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine (2011) 1.02
Hantaviruses in the americas and their role as emerging pathogens. Viruses (2010) 1.02
β2 integrin mediates hantavirus-induced release of neutrophil extracellular traps. J Exp Med (2014) 0.96
T cells and pathogenesis of hantavirus cardiopulmonary syndrome and hemorrhagic fever with renal syndrome. Viruses (2011) 0.94
Granzyme B ELISPOT assay to measure influenza-specific cellular immunity. J Immunol Methods (2013) 0.92
Hantavirus-infection confers resistance to cytotoxic lymphocyte-mediated apoptosis. PLoS Pathog (2013) 0.91
Immunogenetic factors affecting susceptibility of humans and rodents to hantaviruses and the clinical course of hantaviral disease in humans. Viruses (2014) 0.85
Vascular events in viral hemorrhagic fevers: a comparative study of dengue and hantaviruses. Cell Tissue Res (2014) 0.83
The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome. Virulence (2013) 0.83
Hantaan virus infection induces both Th1 and ThGranzyme B+ cell immune responses that associated with viral control and clinical outcome in humans. PLoS Pathog (2015) 0.82
HLA-A2 and B35 restricted hantaan virus nucleoprotein CD8+ T-cell epitope-specific immune response correlates with milder disease in hemorrhagic fever with renal syndrome. PLoS Negl Trop Dis (2013) 0.82
Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines. Front Immunol (2016) 0.79
Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF-α, With Severity of Disease Caused by Andes Virus. Clin Infect Dis (2015) 0.77
Structure and Function of HLA-A*02-Restricted Hantaan Virus Cytotoxic T-Cell Epitope That Mediates Effective Protective Responses in HLA-A2.1/K(b) Transgenic Mice. Front Immunol (2016) 0.77
CD8low CD100- T Cells Identify a Novel CD8 T Cell Subset Associated with Viral Control during Human Hantaan Virus Infection. J Virol (2015) 0.75
What Do We Know about How Hantaviruses Interact with Their Different Hosts? Viruses (2016) 0.75
Screening and Identification of an H-2K(b)-Restricted CTL Epitope within the Glycoprotein of Hantaan Virus. Front Cell Infect Microbiol (2016) 0.75
Enzyme-linked immunospot assay (ELISPOT): Quantification of Th-1 cellular immune responses against microbial antigens. J Vis Exp (2010) 0.75
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Hantaviruses: a global disease problem. Emerg Infect Dis (1997) 9.67
Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol (2002) 9.45
Duration of antiviral immunity after smallpox vaccination. Nat Med (2003) 7.39
Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol (2005) 2.87
Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology (1998) 2.71
Utilization of autopsy RNA for the synthesis of the nucleocapsid antigen of a newly recognized virus associated with hantavirus pulmonary syndrome. Virus Res (1993) 2.57
A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol (2000) 2.26
Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis (2007) 1.97
Secondary replicative function of CD8+ T cells that had developed an effector phenotype. Science (2009) 1.96
IL-7 receptor alpha chain expression distinguishes functional subsets of virus-specific human CD8+ T cells. Blood (2005) 1.95
Person-to-person transmission of Andes virus. Emerg Infect Dis (2005) 1.94
Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation. J Virol (2005) 1.74
Development and evaluation of a solid-phase enzyme immunoassay based on Andes hantavirus recombinant nucleoprotein. J Med Microbiol (2000) 1.70
The pathogenic NY-1 hantavirus G1 cytoplasmic tail inhibits RIG-I- and TBK-1-directed interferon responses. J Virol (2006) 1.66
Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J Immunol (2004) 1.63
Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol (2002) 1.63
Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc Natl Acad Sci U S A (2000) 1.57
Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis (2000) 1.56
An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg Infect Dis (1999) 1.54
Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J Virol (2006) 1.52
Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest (2004) 1.39
Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol (1994) 1.35
Long-lived memory T lymphocyte responses after hantavirus infection. J Exp Med (2002) 1.34
Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol (2003) 1.31
Characterization of glycoproteins of viruses causing hemorrhagic fever with renal syndrome (HFRS) using monoclonal antibodies. Virology (1986) 1.29
Hantavirus pulmonary syndrome. Report of the first three cases in São Paulo, Brazil. Rev Inst Med Trop Sao Paulo (1998) 1.28
DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J Virol (2001) 1.27
The NY-1 hantavirus Gn cytoplasmic tail coprecipitates TRAF3 and inhibits cellular interferon responses by disrupting TBK1-TRAF3 complex formation. J Virol (2008) 1.24
First human isolate of Hantavirus (Andes virus) in the Americas. Emerg Infect Dis (2002) 1.21
Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology (1997) 1.21
Outbreak of hantavirus pulmonary syndrome, Los Santos, Panama, 1999-2000. Emerg Infect Dis (2004) 1.17
Complete nucleotide sequence of a Chilean hantavirus. Virus Res (2002) 1.15
Cellular immune response to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis (2009) 1.13
Antigen-specific CD8+ T cell clonal expansions develop from memory T cell pools established by acute respiratory virus infections. J Immunol (2007) 1.10
Serological evidence of human Hantavirus infection in Argentina, Bolivia and Uruguay. Medicina (B Aires) (1996) 1.10
Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus. J Virol (2009) 1.08
Human CD8+ T cell memory generation in Puumala hantavirus infection occurs after the acute phase and is associated with boosting of EBV-specific CD8+ memory T cells. J Immunol (2007) 1.08
Cell-mediated immunity to virus causing haemorrhagic fever with renal syndrome: generation of cytotoxic T lymphocytes. J Gen Virol (1988) 1.06
Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein. J Virol (1999) 1.05
Serologic evidence of hantavirus infection in humans, Colombia. Emerg Infect Dis (2004) 1.00
Differential susceptibility and resistance of immunocompetent and immunodeficient mice to fatal Hantaan virus infection. Arch Virol (1985) 1.00
Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology (2005) 1.00
Incubation period of hantavirus cardiopulmonary syndrome. Emerg Infect Dis (2006) 0.97
Human recombinant neutralizing antibodies against hantaan virus G2 protein. Virology (2003) 0.96
Degrons at the C terminus of the pathogenic but not the nonpathogenic hantavirus G1 tail direct proteasomal degradation. J Virol (2007) 0.95
Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. J Med Virol (2003) 0.94
Hantavirus-specific CD8(+)-T-cell responses in newborn mice persistently infected with Hantaan virus. J Virol (2003) 0.93
T-helper and humoral responses to Puumala hantavirus nucleocapsid protein: identification of T-helper epitopes in a mouse model. J Gen Virol (2001) 0.92
Immune spleen cell-mediated protection against fatal Hantaan virus infection in infant mice. J Infect Dis (1985) 0.90
Vaccines against hantaviruses. Expert Rev Vaccines (2002) 0.90
Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J Med Virol (2000) 0.89
Analysis of immune responses against nucleocapsid protein of the Hantaan virus elicited by virus infection or DNA vaccination. J Microbiol (2005) 0.88
HLA-B*35-restricted CD8(+)-T-cell epitope in Mycobacterium tuberculosis Rv2903c. Infect Immun (2002) 0.88
Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. J Virol (2002) 0.87
Characterization of HLA-A2.1-restricted epitopes, conserved in both Hantaan and Sin Nombre viruses, in Hantaan virus-infected patients. J Gen Virol (2002) 0.87
Immunization effect of purified bivalent vaccine to haemorrhagic fever with renal syndrome manufactured from primary cultured hamster kidney cells. Chin Med J (Engl) (2005) 0.84
[Genetic susceptibility to Andes Hantavirus: Association between severity of disease and HLA alíeles in Chilean patients]. Rev Chilena Infectol (2007) 0.82
Case report: T-cell responses during clearance of Andes virus from blood cells 2 months after severe hantavirus cardiopulmonary syndrome. J Med Virol (2008) 0.81
Identification of H-2K(b)-restricted T-cell epitopes within the nucleocapsid protein of Hantaan virus and establishment of cytotoxic T-cell clones. J Med Virol (2000) 0.79
Genetic variation and population structure in native Americans. PLoS Genet (2007) 4.87
Geographic patterns of genome admixture in Latin American Mestizos. PLoS Genet (2008) 3.07
Comparison of dengue virus type 2-specific small RNAs from RNA interference-competent and -incompetent mosquito cells. PLoS Negl Trop Dis (2010) 2.18
Persistent Sin Nombre virus infection in the deer mouse (Peromyscus maniculatus) model: sites of replication and strand-specific expression. J Virol (2003) 2.09
Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis (2004) 2.00
Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis (2007) 1.97
Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg (2011) 1.68
Shedding and intracage transmission of Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus) model. J Virol (2002) 1.62
Identification of rodent homologs of hepatitis C virus and pegiviruses. MBio (2013) 1.61
[Utility of real time polymerase chain reaction in the diagnosis of respiratory syncytial virus infection among adult patients]. Rev Chilena Infectol (2007) 1.40
Genetic interaction between distinct Dobrava hantavirus subtypes in Apodemus agrarius and A. flavicollis in nature. J Virol (2003) 1.32
Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol (2010) 1.31
Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus. Proc Natl Acad Sci U S A (2007) 1.28
Emerging viruses: the case 'hantavirus'. Intervirology (2002) 1.27
Ecology, genetic diversity, and phylogeographic structure of andes virus in humans and rodents in Chile. J Virol (2008) 1.24
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem (2013) 1.24
Induction of innate immune response genes by Sin Nombre hantavirus does not require viral replication. J Virol (2005) 1.20
Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis (2006) 1.18
DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLoS One (2012) 1.18
Sin Nombre viral RNA load in patients with hantavirus cardiopulmonary syndrome. J Infect Dis (2006) 1.14
Contrasting patterns of nuclear and mtDNA diversity in Native American populations. Ann Hum Genet (2010) 1.07
Peridomestic small mammals associated with confirmed cases of human hantavirus disease in southcentral Chile. Am J Trop Med Hyg (2004) 1.05
Hantavirus prevalence in the IX Region of Chile. Emerg Infect Dis (2003) 1.05
Early innate immune responses to Sin Nombre hantavirus occur independently of IFN regulatory factor 3, characterized pattern recognition receptors, and viral entry. J Immunol (2007) 1.04
High seroprevalence of hantavirus infection on the Azuero peninsula of Panama. Am J Trop Med Hyg (2004) 1.04
Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model. J Gen Virol (2007) 1.02
Hantavirus infection and habitat associations among rodent populations in agroecosystems of Panama: implications for human disease risk. Am J Trop Med Hyg (2009) 0.99
On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol Dis (2004) 0.98
New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells. PLoS One (2010) 0.98
Kinetics of immune responses in deer mice experimentally infected with Sin Nombre virus. J Virol (2012) 0.98
Person-to-person household and nosocomial transmission of andes hantavirus, Southern Chile, 2011. Emerg Infect Dis (2014) 0.97
Osteoarthritis-associated basic calcium phosphate crystals induce pro-inflammatory cytokines and damage-associated molecules via activation of Syk and PI3 kinase. Clin Immunol (2012) 0.97
Incubation period of hantavirus cardiopulmonary syndrome. Emerg Infect Dis (2006) 0.97
Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Int J Infect Dis (2007) 0.97
Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant (2009) 0.96
Peptide antagonists that inhibit Sin Nombre virus and hantaan virus entry through the beta3-integrin receptor. J Virol (2005) 0.96
Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology. Swiss Med Wkly (2014) 0.95
The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells (2012) 0.95
Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg Infect Dis (2004) 0.94
Experimental Andes virus infection in deer mice: characteristics of infection and clearance in a heterologous rodent host. PLoS One (2013) 0.94
Andes virus antigens are shed in urine of patients with acute hantavirus cardiopulmonary syndrome. J Virol (2009) 0.94
[Seroprevalence of antibodies against hantavirus in 10 communities of the IX Region of Chile where hantavirus infection were diagnosed]. Rev Med Chil (2002) 0.94
Serological assays for the detection of human andes hantavirus infections based on its yeast-expressed nucleocapsid protein. Intervirology (2006) 0.93
[Genetic composition of the Chilean population. Analysis of mitochondrial DNA polymorphism]. Rev Med Chil (2002) 0.93
An alternative model for the early peopling of southern South America revealed by analyses of three mitochondrial DNA haplogroups. PLoS One (2012) 0.93
High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis (2013) 0.92
Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus). J Gen Virol (2002) 0.92
[Molecular and genetic characterization of Changos descendants living in Paposo Cove]. Rev Med Chil (2004) 0.91
A preliminary study of the patterns of Sin Nombre viral infection and shedding in naturally infected deer mice (Peromyscus maniculatus). Vector Borne Zoonotic Dis (2005) 0.91
Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection. Emerg Infect Dis (2006) 0.91
Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component. Neurosci Lett (2007) 0.90
Fatal hemorrhagic pneumonia caused by human metapneumovirus in an immunocompetent child. Pediatr Int (2008) 0.90
Development and evaluation of serological assays for detection of human hantavirus infections caused by Sin Nombre virus. J Clin Virol (2005) 0.89
Hantavirus fever without pulmonary syndrome in Panama. Am J Trop Med Hyg (2013) 0.88
Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol (2005) 0.88
Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease. Neurotox Res (2007) 0.88
Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome. J Virol (2002) 0.88
Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade. Antimicrob Agents Chemother (2008) 0.88
Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol (2004) 0.87
[The new-world hantaviruses. Ecology and epidemiology of an emerging virus in Latin America]. Medicina (B Aires) (2006) 0.87
mtDNA microevolution in Southern Chile's archipelagos. Am J Phys Anthropol (2006) 0.87
Rapid and simple method for screening wild rodents for antibodies to Sin Nombre hantavirus. J Wildl Dis (2003) 0.87
Dengue-1 virus isolation during first dengue fever outbreak on Easter Island, Chile. Emerg Infect Dis (2003) 0.87
Recognition of decay accelerating factor and alpha(v)beta(3) by inactivated hantaviruses: Toward the development of high-throughput screening flow cytometry assays. Anal Biochem (2010) 0.87
The antidiabetic effect of MSCs is not impaired by insulin prophylaxis and is not improved by a second dose of cells. PLoS One (2011) 0.87
[Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults]. Rev Med Chil (2002) 0.86
Spatial but not temporal co-divergence of a virus and its mammalian host. Mol Ecol (2011) 0.84
A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir Ther (2014) 0.84
Hantavirus infection in children. Curr Opin Pediatr (2004) 0.84
Profiling helper T cell subset gene expression in deer mice. BMC Immunol (2006) 0.83
Characterization of monoclonal antibodies against hantavirus nucleocapsid protein and their use for immunohistochemistry on rodent and human samples. Arch Virol (2010) 0.82
Selection and characterization of scFv antibodies against the Sin Nombre hantavirus nucleocapsid protein. J Immunol Methods (2007) 0.82
Case report: T-cell responses during clearance of Andes virus from blood cells 2 months after severe hantavirus cardiopulmonary syndrome. J Med Virol (2008) 0.81
Recommendations for publication of viral genetic data and sample access for novel viruses and strains. Am J Trop Med Hyg (2012) 0.81
Incidence rate for hantavirus infections without pulmonary syndrome, Panama. Emerg Infect Dis (2011) 0.81
Phage display selection of cyclic peptides that inhibit Andes virus infection. J Virol (2009) 0.81
Young man with kidney failure and hemorrhagic interstitial nephritis. Am J Kidney Dis (2009) 0.81
[Etiology of pneumonia in chilean HIV-infected adult patients]. Rev Chilena Infectol (2011) 0.80
Effects of heavy metals on immunocompetence of white-footed mice (Peromyscus leucopus). J Wildl Dis (2004) 0.79
Andes virus infections in the rodent reservoir and in humans vary across contrasting landscapes in Chile. Infect Genet Evol (2009) 0.79
Sin Nombre virus infection in field workers, Colorado, USA. Emerg Infect Dis (2010) 0.79
[Influenza-A as etiology of fever and respiratory insufficiency in adults hospitalized during an outbreak in Chile]. Rev Med Chil (2004) 0.78
Small molecule inhibitors of hantavirus infection. Bioorg Med Chem Lett (2010) 0.78
New norovirus classified as a recombinant GII.g/GII.1 causes an extended foodborne outbreak at a university hospital in Munich. J Clin Virol (2013) 0.78
[Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol (2005) 0.78
Dendritic and stromal cells from the spleen of lupic mice present phenotypic and functional abnormalities. Mol Immunol (2013) 0.78